Chungdam Global Q1 2026: OP 2.55B won, Net Profit 7.57B won, Issued 32.8B won BW
Consolidated Q1 2026: Revenue 48.3B won (down 11.0% from 54.3B won in prior quarter), Operating Profit 2.55B won, Net Profit 7.57B won (up 180% from 2.70B won, including non-operating income of 10.24B won from bond redemption gain of 3.73B won).
On Feb 12, 2026, issued 11th unregistered private BW of 32.8B won (maturity 2029, coupon 0%, yield-to-maturity 4%, exercise price 6,951 won, 4,718,745 new shares).
On Dec 15, 2025, issued 10th unregistered private exchangeable bonds of 6.66B won (maturity 2030, exchange price 8,297 won, exchangeable into 802,817 treasury shares).
During Q1, the 9th CB (20B won) was fully redeemed via put option exercise, recognizing a bond redemption gain of 3.73B won.
Treasury shares: 802,817 shares held (book value 4.998B won), deposited for exchangeable bonds.
Consolidated total borrowings: 73.18B won (up from 69.00B won at year-end 2025), net debt ratio 33.0% (28.3% at year-end).
Consolidated cash and cash equivalents: 7.15B won (down 68.4% from 22.62B won at year-end).
Major subsidiaries: BioBijou (revenue 8.01B won, OP 2.62B won); Kreassive INC (revenue 4.11B won, OP 54M won).
Consolidated EPS 309 won (122 won in prior quarter), separate EPS 303 won (87 won in prior quarter).